SVP of Clinical, Quality, & Regulatory Affairs Michael Nketiah resigns effective Aug 16, 2024

Nexalin Technology, Inc.

Michael Nketiah resigned as SVP of Clinical, Quality, & Regulatory Affairs, effective August 16, 2024.
Departure is to pursue another professional opportunity; no disagreement with the company.
He will continue serving until the effective date.
No successor has been named in the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Nketiah

Senior Vice President of Clinical, Quality, & Regulatory Affairs

NXL · Nexalin Technology, Inc.

Effective: 2024-08-16
Filed: July 30, 2024, 7:59 PM ET

On July 29, 2024, Michael Nketiah submitted his resignation as the Senior Vice President of Clinical, Quality, & Regulatory Affairs of Nexalin Technology Inc. (the "Company").

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Nketiah resigned as Senior Vice President of Clinical, Quality, & Regulatory Affairs at Nexalin Technology, Inc..

Action: resigned
Role: Senior Vice President of Clinical, Quality, & Regulatory Affairs

Exact text from the filing

On July 29, 2024, Michael Nketiah submitted his resignation as the Senior Vice President of Clinical, Quality, & Regulatory Affairs of Nexalin Technology Inc. (the "Company").

View on SEC.gov

Nexalin Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-24-005111

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.